Pivotal Life Sciences Congratulates MapLight Therapeutics and Evommune, Inc. On Successful IPOs

San Francisco, Calif. – December 3, 2025 – Pivotal Life Sciences, a global investment firm dedicated to investing in companies involved in healthcare innovation seeking to improve patient outcomes, today announced that two of its portfolio companies, MapLight Therapuetics (NASDAQ: MPLT) and Evommune, Inc. (NYSE: EVMN) have successfully completed their initial public offerings. These milestones mark important achievements for both companies and signal renewed momentum in the biotechnology IPO market.

Pivotal Life Sciences has been deeply involved in the creation and development of both companies, supporting each from inception through multiple stages of growth. The firm partnered closely with founding scientists and management teams to establish each company's strategic foundation, recruit key leaders and guide their financing and development through to the public markets.

"Our focus has always been to build enduring organizations grounded in strong science and purpose," said Rob Hopfner, Managing Director at Pivotal Life Sciences. "Seeing MapLight and Evommune reach the public markets underscores what is possible when that philosophy meets the right teams and therapies."

Managing Director Peter Bisgaard added, "Our companies' IPOs underscore what can be achieved when visionary science meets disciplined, long-term company building. These successes also mark an important moment for the broader biotech ecosystem as public investors re-engage with high-quality innovation."

MapLight is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, including schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder. Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases.

About Pivotal Life Sciences

With more than $2 billion under management, Pivotal Life Sciences is an asset management platform focused on investing in therapeutic innovation worldwide, across asset classes and spanning all stages of company development.

For more information visit www.pivotallifesciences.com